Maturity-Onset Diabetes of the Young (MODY): Making the Right Diagnosis to Optimize Treatment

Canadian Journal of Diabetes

Volumn 40, Issue 5, 2016, Pages 449-454

  Amed, Shazhan ^a   Oram, Richard ^b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

diabetes; glucokinase; hepatic nuclear factor; maturity onset diabetes of the young (MODY); monogenic

Indexed keywords

GLICLAZIDE; GLUCOKINASE; GLUCOSE; HEMOGLOBIN A1C; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; INSULIN; MEGLITINIDE; SULFONYLUREA DERIVATIVE;

AUTOSOMAL DOMINANT INHERITANCE; CLINICAL FEATURE; DIET; FAMILY HISTORY; GENE MUTATION; GENETIC SCREENING; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MOLECULAR DIAGNOSIS; MONOGENIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PREGNANCY DIABETES MELLITUS; PREVALENCE; QUALITY OF LIFE; REVIEW; ADOLESCENT; CHILD; CLINICAL PROTOCOL; DIABETES MELLITUS; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; PRACTICE GUIDELINE; RARE DISEASES;

ADOLESCENT; CHILD; CLINICAL PROTOCOLS; DIABETES MELLITUS; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC ERRORS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; RARE DISEASES;

EID: 84964675016     PISSN: 14992671     EISSN: 23523840     Source Type: Journal    
DOI: 10.1016/j.jcjd.2016.03.002     Document Type: Review

References (43)

1. 1 Patterson, C., Guariguata, L., Dahlquist, G., et al. Diabetes in the young: A global view and worldwide estimates of numbers of children with type 1 diabetes. Diabetes Res Clin Pract 103 (2014), 161–175.
2. 2 Rubio-Cabezas, O., Hattersley, A.T., Njølstad, P.R., et al. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 15 (2014), 47–64.
3. 3 Schwitzgebel, V.M., Many faces of monogenic diabetes. J Diabetes Investig 5 (2014), 121–133.
4. 4 McDonald, T.J., Ellard, S., Maturity onset diabetes of the young: Identification and diagnosis. Ann Clin Biochem 50:Pt 5 (2013), 403–415.
5. 5 Shields, B.M., Hicks, S., Shepherd, M.H., et al. Maturity-onset diabetes of the young (MODY): How many cases are we missing?. Diabetologia 53 (2010), 2504–2508.
6. 6 Pihoker, C., Gilliam, L.K., Ellard, S., et al. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: Results from the SEARCH for Diabetes in Youth. J Clin Endocrinol Metab 98 (2013), 4055–4062.
7. 7 Chambers, C., Fouts, A., Dong, F., et al. Characteristics of maturity onset diabetes of the young in a large diabetes center. Pediatr Diabetes, 2015 Epub ahead of print.
8. 8 Gandica, R.G., Chung, W.K., Deng, L., et al. Identifying monogenic diabetes in a pediatric cohort with presumed type 1 diabetes. Pediatr Diabetes 16 (2014), 227–233.
9. 9 Amed, S., Dean, H.J., Panagiotopoulos, C., et al. Type 2 diabetes, medication-induced diabetes, and monogenic diabetes in Canadian children: A prospective national surveillance study. Diabetes Care 33 (2010), 786–791.
10. 10 Cammidge, P.J., Diabetes mellitus and heredity. BMJ 2 (1928), 738–741.
11. 11 Tattersall, R.B., Mild familial diabetes with dominant inheritance. Q J Med 43 (1974), 339–357.
12. 12 Tallapragada, D.S.P., Bhaskar, S., Chandak, G.R., New insights from monogenic diabetes for “common” type 2 diabetes. Front Genet, 6, 2015, 251.
13. 13 Ellard, S., Bellanné-Chantelot, C., Hattersley, A.T., European Molecular Genetics Quality Network (EMQN) MODY group. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 51 (2008), 546–553.
14. 14 Stanik, J., Dusatkova, P., Cinek, O., et al. De novo mutations of GCK, HNF1A and HNF4A may be more frequent in MODY than previously assumed. Diabetologia 57 (2014), 480–484.
15. 15 Osbak, K.K., Colclough, K., Saint-Martin, C., et al. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat 30 (2009), 1512–1526.
16. 16 Chakera, A.J., Spyer, G., Vincent, N., et al. The 0.1% of the population with glucokinase monogenic diabetes can be recognized by clinical characteristics in pregnancy: The Atlantic Diabetes in Pregnancy Cohort. Diabetes Care 37 (2014), 1230–1236.
17. 17 Stride, A., Vaxillaire, M., Tuomi, T., et al. The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia 45 (2002), 427–435.
18. 18 Steele, A.M., Shields, B.M., Wensley, K.J., et al. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA 311 (2014), 279–286.
19. 19 Spyer, G., Macleod, K.M., Shepherd, M., et al. Pregnancy outcome in patients with raised blood glucose due to a heterozygous glucokinase gene mutation. Diabet Med 26 (2009), 14–18.
20. 20 Hattersley, A.T., Beards, F., Ballantyne, E., et al. Mutations in the glucokinase gene of the fetus result in reduced birth weight. Nat Genet 19 (1998), 268–270.
21. 21 Singh, R., Pearson, E.R., Clark, P.M., Hattersley, A.T., The long-term impact on offspring of exposure to hyperglycaemia in utero due to maternal glucokinase gene mutations. Diabetologia 50 (2007), 620–624.
22. 22 Pearson, E.R., Pruhova, S., Tack, C.J., et al. Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4alpha mutations in a large European collection. Diabetologia 48 (2005), 878–885.
23. 23 Murphy, R., Ellard, S., Hattersley, A.T., Clinical implications of a molecular genetic classification of monogenic β-cell diabetes. Nat Clin Pract Endocrinol Metab 4 (2008), 200–213.
24. 24 Bellanné-Chantelot, C., Carette, C., Riveline, J.-P., et al. The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3. Diabetes 57 (2008), 503–508.
25. 25 Pontoglio, M., Prié, D., Cheret, C., et al. HNF1alpha controls renal glucose reabsorption in mouse and man. EMBO Rep 1 (2000), 359–365.
26. 26 McDonald, T.J., McEneny, J., Pearson, E.R., et al. Lipoprotein composition in HNF1A-MODY: Differentiating between HNF1A-MODY and type 2 diabetes. Clin Chim Acta 413 (2012), 927–932.
27. 27 Steele, A.M., Shields, B.M., Shepherd, M., et al. Increased all-cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene. Diabet Med 27 (2010), 157–161.
28. 28 Pearson, E.R., Boj, S.F., Steele, A.M., et al. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLoS Med, 4, 2007, e118.
29. 29 Flanagan, S.E., Kapoor, R.R., Mali, G., et al. Diazoxide-responsive hyperinsulinemic hypoglycemia caused by HNF4A gene mutations. Eur J Endocrinol 162 (2010), 987–992.
30. 30 Kapoor, R.R., Locke, J., Colclough, K., et al. Persistent hyperinsulinemic hypoglycemia and maturity-onset diabetes of the young due to heterozygous HNF4A mutations. Diabetes 57 (2008), 1659–1663.
31. 31 Besser, R.E., Shields, B.M., Hammersley, S.E., et al. Home urine C-peptide creatinine ratio testing can identify type 2 and MODY in pediatric diabetes. Pediatr Diabetes 14 (2013), 181–188.
32. 32 McDonald, T.J., Colclough, K., Brown, R., et al. Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from type 1 diabetes. Diabet Med 28 (2011), 1028–1033.
33. 33 Harries, L.W., Sloman, M.J., Sellers, E.A.C., et al. Diabetes susceptibility in the Canadian Oji-Cree population is moderated by abnormal mRNA processing of HNF1A G319S transcripts. Diabetes 57 (2008), 1978–1982.
34. 34 Sellers, E.A.C., Triggs-Raine, B., Rockman-Greenberg, C., Dean, H.J., The prevalence of the HNF-1alpha G319S mutation in Canadian aboriginal youth with type 2 diabetes. Diabetes Care 25 (2002), 2202–2206.
35. 35 Bingley, P.J., Clinical applications of diabetes antibody testing. J Clin Endocrinol Metab 95 (2010), 25–33.
36. 36 Besser, R.E.J., Ludvigsson, J., Jones, A.G., et al. Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. Diabetes Care 34 (2011), 607–609.
37. 37 Besser, R.E.J., Shepherd, M.H., McDonald, T.J., et al. Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes. Diabetes Care 34 (2011), 286–291.
38. 38 Thanabalasingham, G., Pal, A., Selwood, M.P., et al. Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young. Diabetes Care 35 (2012), 1206–1212.
39. 39 Jones, A.G., Hattersley, A.T., The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med 30 (2013), 803–817.
40. 40 Owen, K.R., Thanabalasingham, G., James, T.J., et al. Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations. Diabetes Care 33 (2010), 1919–1924.
41. 41 Shields, B.M., McDonald, T.J., Ellard, S., et al. The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes. Diabetologia 55 (2012), 1265–1272.
42. 42 Shepherd, M., Pearson, E.R., Houghton, J., et al. No deterioration in glycemic control in HNF-1alpha maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas. Diabetes Care 26 (2003), 3191–3192.
43. 43 Raile, K., Schober, E., Konrad, K., et al. Treatment of young patients with HNF1A mutations (HNF1A-MODY). Diabet Med 32 (2015), 526–530.